Business ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials GLP-1 Drugs Weight Loss Drugs Acquisitions Eli Lilly Obesity Drugs Oncology Eli Lilly and Company Cancer Treatment Novo Nordisk

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion to Bolster Eye Pipeline

The purchase secures PER-001 for Bayer, a Phase II eye implant that blocks endothelin to treat leading causes of vision loss.

Stories older than 24h

ADC Therapeutics Reports Higher Q1 Sales and Lower Costs as Zenlonta Readouts Near

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

AbbVie Tops Q1 and Raises 2026 Outlook as Skyrizi and Rinvoq Offset Humira Decline

Sun Pharma Said to Make $13 Billion All-Cash Offer for Organon

Cramer Touts Intel Comeback Under Lip‑Bu Tan as Earnings Loom

Novo Nordisk Partners With OpenAI to Speed Drug Development and Operations

Boehringer Ingelheim Transfers CT-155 Commercial Rights to Click Therapeutics With $50 Million Backing

Bank of America Cuts Hims & Hers Target as GLP‑1 Pivot Squeezes Margins

Neurocrine to Acquire Soleno for $2.9 Billion in All-Cash Tender

EPO Signals Patent Grant for Silo Pharma’s PTSD Prevention Approach

Fosun Reports 2025 Results With RMB23.4 Billion in Write-Downs and a Higher 2026 Payout Target

Bristol Gate’s Q4 Letter Reaffirms Dividend-Growth Focus as Market Breadth Improves

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Sanofi Licenses Kali’s Tri-Specific Autoimmune Antibody KT501 in Deal Worth Up to $1.23 Billion

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Roche Expands NVIDIA Partnership, Building Pharma’s Largest Hybrid‑Cloud AI Factory

Novo Nordisk Strikes Hims & Hers Deal for Ozempic and Wegovy, Drops Patent Suit